Bristol Myers Squibb's Cancer Drug Opdivo Successful in 2 Clinical Trials [The Motley Fool]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: The Motley Fool
Brian Orelli(TMFBiologyFool)Author BioDr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 007.Follow @BiologyFoolBristol Myers SquibbNYSE:BMYIn the CheckMate-9ER clinical trial, the combination of Opdivo andExelixisNASDAQ:EXELPfizerNYSE:PFEOpdivo is already approved for use in combination with Bristol Myers Squibb's Yervoy in patients with previously untreated kidney cancer, so the results are a bigger deal for Exelixis than the largerpharmaceutical companyImage source: Getty Images.In the mesothelioma trial, CheckMate-7, Opdivo plus Yervoy improved overall survival compared to standard chemotherapy. And here too, Bristol Myers is saving the data to be released at an upcoming medical meeting.Opdivo is approved by the Food and Drug Administration to treat different types of cancer. The drug works by blocking a protein called programmed death receptor- (PD-) on immune cells that tumor cells use
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Is Bristol Myers Squibb Stock a Buy? [Yahoo! Finance]Yahoo! Finance
- Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks [Yahoo! Finance]Yahoo! Finance
- Effervescent Tablet Market to Grow by USD 4.80 Billion (2024-2028) as AI Impacts Market Trends, Rising Adoption Among Aging Population Boosts Revenue - Technavio [Yahoo! Finance]Yahoo! Finance
- Transplant Therapeutics Consortium Receives FDA Acceptance of the Qualification Plan for iBox Scoring System [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]Yahoo! Finance
BMY
Earnings
- 10/31/24 - Beat
BMY
Sec Filings
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- 11/5/24 - Form 4
- BMY's page on the SEC website